✦ LIBER ✦

Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab

✍ Scribed by Ori Elkayam; Philip N. Hawkins; Helen Lachmann; Michael Yaron; Dan Caspi

Publisher: John Wiley and Sons
Year: 2002
Tongue: English
Weight: 31 KB
Volume: 46
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.10581

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

We describe herein a patient with rheumatoid arthritis who developed proteinuria due to AA amyloidosis, in whom the inflammatory disease was rapidly and completely suppressed by treatment with infliximab. This response was accompanied by resolution of the proteinuria and stabilization of the amyloid deposits as seen on serial ^123^I‐labeled serum amyloid P scintigraphy.

📜 SIMILAR VOLUMES

Improvement of renal function and disapp

Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab

✍ Maria Grazia Anelli; Diletta Domenica Torres; Carlo Manno; Crescenzio Scioscia; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 38 KB 👁 2 views

Reactive systemic AA amyloidosis is a severe complication of rheumatoid arthritis (RA), occurring in 2-5% of RA patients (1). Infliximab, a monoclonal antibody against tumor necrosis factor ␣ (TNF␣), is successfully used in the treatment of RA (2). TNF␣ plays a key role in inducing the synthesis of

Pneumocystis jirovecipneumonia in patien

Pneumocystis jirovecipneumonia in patients with rheumatoid arthritis treated with infliximab: A retrospective review and case-control study of 21 patients

✍ Komano, Yukiko ;Harigai, Masayoshi ;Koike, Ryuji ;Sugiyama, Haruhito ;Ogawa, Jun 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB 👁 2 views

C-reactive protein as a predictor of inf

C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: Defining subtypes of nonresponse and subsequent response to etanercept

✍ Maya H. Buch; Yohei Seto; Sarah J. Bingham; Victoria Bejarano; Domini Bryer; Jo 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 2 views

Ultrasonographic and radiographic result

Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year–delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis

✍ P. C. Taylor; A. Steuer; J. Gruber; C. McClinton; D. O. Cosgrove; M. J. K. Bloml 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB 👁 1 views

Assessment of antibodies to double-stran

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: Findings in open-label and randomized placebo-controlled trials

✍ P. J. Charles; R. J. T. Smeenk; J. De Jong; M. Feldmann; R. N. Maini 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB 👁 2 views

Objective. To compare the incidence of antidouble-stranded DNA (anti-dsDNA) antibodies in rheumatoid arthritis (RA) patients receiving either single or multiple doses of a chimeric anti-tumor necrosis factor ␣ (anti-TNF␣) antibody or placebo infusions, with or without methotrexate, in open-label, ra

Rapid and sustained improvement in bone

Rapid and sustained improvement in bone and cartilage turnover markers with the anti–interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone

✍ Patrick Garnero; Elizabeth Thompson; Thasia Woodworth; Josef S. Smolen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 276 KB 👁 2 views

## Abstract ## Objective To investigate the effects of tocilizumab (TCZ) added to a stable dosage of methotrexate (MTX) on biochemical markers of bone and cartilage metabolism in patients in the multicenter double‐blind, placebo‐controlled OPTION (Tocilizumab Pivotal Trial in Methotrexate Inadequa